Free Trial

InMode Q4 2023 Earnings Report

InMode logo
$17.08 -0.11 (-0.64%)
(As of 12/20/2024 05:40 PM ET)

InMode EPS Results

Actual EPS
$0.71
Consensus EPS
$0.66
Beat/Miss
Beat by +$0.05
One Year Ago EPS
$0.69

InMode Revenue Results

Actual Revenue
$126.80 million
Expected Revenue
$124.77 million
Beat/Miss
Beat by +$2.03 million
YoY Revenue Growth
-5.10%

InMode Announcement Details

Quarter
Q4 2023
Time
Before Market Opens

Conference Call Resources

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

InMode Earnings Headlines

Analysts Set InMode Ltd. (NASDAQ:INMD) Price Target at $22.60
Your chance to get on the next “60-Second Trade”
Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!
See More InMode Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InMode? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InMode and other key companies, straight to your email.

About InMode

InMode (NASDAQ:INMD) designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

View InMode Profile

More Earnings Resources from MarketBeat

Upcoming Earnings